Reinsurance Group of America (RGA) has been upgraded to "Buy" from "Neutral" by UBS. Trinseo has been upgraded to "Overweight" from "Neutral" by Alembic Global. PPD, Inc.'s price target has been raised to $40 from $36 at Baird. Seres Therapeutics' price target has been raised to $42 from $38 at Canaccord. CorMedix has been started with a "Buy" rating at Truist due to the potential of Defencath. Coupa Software's price target has been raised to $330 from $272 at Morgan Stanley.